Psychedelics – reasons for caution: Stacy Fischer, Brian Anderson, Theora Cimino
GeriPal
MARCH 9, 2023
FDA is considering approval, shifting away from Schedule I restrictions, paving the way for use in clinical practice. In our prior podcast with Ira Byock on psychedelics in 2019 we talked primarily about the potential of psychedelics. I’m part of a clinical trial that’s housed at the Lundquist Institute down at Harbor-UCLA.
Let's personalize your content